



Original article

Non-alcoholic fatty liver disease and neurological defects[☆]Rita Moretti^{a,*}, Paola Caruso^a, Silvia Gazzin^b^a Neurology Clinic, Department of Medical, Surgical, and Health Sciences, University of Trieste, Trieste, Italy^b Italian Liver Foundation, Centro Studi Fegato, Trieste, Italy

ARTICLE INFO

Article history:

Received 1 February 2019

Accepted 11 April 2019

Available online 6 May 2019

Keywords:

Liver steatosis

Vascular risk factors

Neurological disorders

Behavior diseases

ABSTRACT

Introduction and Objectives: Nonalcoholic fatty liver disease (NAFLD) can be considered one of the most common causes of liver disease in our days and is regarded as one of the newest vascular risk factors for cerebrovascular and other neurological diseases.

Materials and methods: We studied a group of neurological outpatients, divided into two homogenous groups based on the presence or absence of NAFLD.

Results and conclusions: We testified an independent relationship between NAFLD and common vascular risk factors (age, sex, educational level, BMI, cholesterol and lipid assessment, Hb1ac). At the same time, we ascertained an independent relationship between NAFLD and more recently recognized vascular risk factors, such as lack of folate, vitamin B12 and vitamin D-OH25, and increased levels of homocysteine. Finally, we have documented that NAFLD showed worse executive and frontal functions, and behavioral changes, such as depressive mood and anxiety, and apathy.

© 2019 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Non-alcoholic fatty liver disease (NAFLD) was defined as “mild, moderate or severe steatosis as determined by ultrasound, in the absence of elevated alcohol consumption” (generally estimated as more than 20 g/day for women and more than 30 g/day for men), and in the absence of a positive test for viral hepatitis B or C [1,2]. NAFLD is considered one of the most common causes of chronic liver disease [3–5]. It has been reported that it is gradually becoming one of the most prevalent liver diseases, identified on imaging in 20–33% of adults [1,6,7].

NAFLD has been recently associated with cardiovascular disease and is linked with vascular risk factors, such as obesity, hypertension, type 2 diabetes, dyslipidemia [8–10]. Some studies [4,11] also proposed that NAFLD could be considered an independent vascular risk factor. Won Seo et al. [3] hypothesized for the first time that NAFLD could be independently associated with cognitive impairment.

Our study was aimed to find a possible independent relationship with more recently recognized vascular risk factors, such as lack of folate, vitamin B12 and vitamin D-OH25, and increased lev-

els of homocysteine [12–16]. Moreover, we want to determine a possible independent relationship with cognitive and behavioral changes, such as frontal executive functions and divided attention, depression, anxiety, and apathy, not, to the best of our knowledge, together previously studied.

1.1. Subjects characteristics

The study included 1358, consecutive cases of adult patients referred to the Neurological Unit of the University of Trieste, from June 1st, 2008 to June 1st, 2016. Their referral to Neurological Unit was determined by different diagnosis: 743 suffering from cervicogenic headaches, 307 suffering from a migraine, and 308 due to a single transient ischemic attack. Study subjects underwent a standardized baseline assessment, that included: a detailed history; a physical examination; laboratory tests; neuropsychological evaluations; an abdominal echography; a carotid Doppler ultrasonography. The physical examination included cardiac and blood pressure evaluation, peripheral pulses, retinal vessel exploration, electrocardiographic evaluation. All the patients were evaluated with a complete neurological examination and completed the test with a series of neuropsychological examination.

All the recruited participants underwent a gallbladder and liver examination by ultrasound with a TOSHIBA SSA-907 machine with a 3.75 and 5.0MHz transducer data concerning the presence of kidney to liver contrast, echogenic walls within the intrahepatic vessels and deep beam attenuation, associated with the bright-

[☆] The authors thank Mr. Andrew Highgate for the revision of the manuscript.

* Corresponding author at: Neurology Clinic, Department of Medical, Surgical, and Health Sciences, University of Trieste, Trieste, Italy.

E-mail address: moretti@units.it (R. Moretti).

ness of the liver parenchyma and gallbladder walls was obtained. We applied a standardized algorithm, to define the extension of the steatosis as a 4 level classification (1: none; 2: mild; 3: moderate; 4: severe steatosis). Patients were divided into two groups according to the presence or absence of NAFLD. 671 patients were affected by NAFLD: among them, 359 suffered from cervicogenic headaches (Group A), 161 suffering from a migraine (Group B), and 151 due to a single transient ischemic attack (Group C). Among the 687 patients without NAFLD (Group D) 384 suffered from a cervicogenic headache, 146 from a migraine and 157 had a single transient ischemic attack. Group D was considered the control population.

Standard questionnaires were conducted with all participants and included alcohol consumption, smoking, drug use, and physical activity.

The present study was conducted following the Declaration of Helsinki, and under the Ethics Guidelines (Point 4 of the CEUR Declaration) of the Committee of the University – Hospital of Trieste, and written informed consent was obtained from all the participants.

2. Methods

Diabetes mellitus was defined as venous plasma glucose concentrations of >120 mg/dl after an overnight fast. Glycated hemoglobin (Hb1Ac) results have been aligned to the assay applied by the Diabetes Control and Complication Trial (DCCT), expressed as a percentage; non-diabetic normal range has been considered a level 4–5.6%; 5.5–6.5% indicates a high risk of developing diabetes; a value superior to 6.6% indicates diabetes [17,18]. Clinical measurement included: total serum cholesterol, triglycerides, and high-density lipoprotein (HDL), low-density lipoprotein (LDL) was calculated by Friedwald's formula [19]. Serum level of folate, vitamin B12 and homocysteine were also tested, as specific measures of vascular risk factors. Liver enzymes, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), as well as a second generation enzyme Immuno-assay (Abbott Laboratories, Chicago, IL) was employed to detect the presence of hepatitis C antibodies, while a solid phase competitive immunoassay (Abbott Laboratories) was used to detect antibodies to the hepatitis B core antigen. Serum levels of 25 (OH)D vitamin were measured using enzyme immune-assay kits (DIA Source ImmunoAssay, SA Belgium) and the classification of vitamin D following the National Osteoporosis Society [20].

Standard questionnaires were conducted with all participants and included alcohol consumption (AUDIT), smoking, drug use, and physical activity.

We obtained the average daily estimate for alcohol consumption as an amount less than 20 g/day for women and less than 30 g/day for men [21–23].

The body mass index (BMI) was calculated. Vascular impairment, tumor, or CNS primary inflammatory or degenerative disease were excluded by a head CT/MRI scan.

An Ultrasonography Carotid examination has been done to all the patients.

All the patients underwent a simple sequence of neuropsychological tests:

1. Frontal Assessment Battery (FAB; score: 0–18; 18 = normal) [24,25].
2. Beck's Depression Inventory (version for Italian population) (score: 0–39; total score 10–19 indicated mild depression; total score 20–29 indicated moderate depression; >30 indicated severe depression) [26,27].

3. Hamilton Anxiety Rating Scale (HAM-A) (score: 0–56; a total score comprised 0–17, estimated mild anxiety; 18–24: mild to moderate anxiety; 25–30: severe anxiety) [28].
4. Apathy Evaluation Score (AES-C) (clinical examination; score: 18–72; higher scores reflect more apathy) [29].
5. Stroop Test (reading, color naming, and interference mistakes) [30,31].

2.1. Statistical analysis

Statistical analysis was performed with SPSS statistics 17.0 (SPSS version 17.0). The difference in baseline characteristics between the NAFLD and no NAFLD patients was assessed by ANOVA test, for categorical variables; in case the ANOVA results were found significant, the multiple comparison analysis was also done by the Tukey Test, to examine those groups, which were significantly different from each other. The multinomial logistic regression method was applied to analyze the relationship between disease status (NAFLD and control) considering them as the dependent variable (non-metric), and age (metric), sex (non-metric), Labs values (all metrics) as independent variables.

To evaluate the relationship between NAFLD and cognitive and behavioral results, we performed a multivariate linear regression analysis.

In model 1, we adjusted for sex, age, race, and educational levels; in model 2 we further adjusted for vitamin D-OH25, folate, vitamin B12, and homocysteine levels.

3. Results

We recruited 1358 consecutive patients. 671 patients were affected by NAFLD. 687 did not suffer from NAFLD (Group D) and were considered as healthy controls.

Among the 671 NAFLD patients enrolled, five patients abandoned the study, 13 were excluded for lack of compliance, 653 patients completed the study. Group A included 341 patients; Group B enrolled 155 patients, and Group C comprised 151 patients, for a total of 647 patients.

In Group D, composed initially by 687 healthy controls, 12 patients abandoned the study and 22 were excluded for the lack of compliance. Therefore, Group D finally comprised of 653 patients.

By definition, NAFLD did not have HBV or HCV virus Antibodies; In group A (341 patients), 83 (24.3%) showed grade 2 steatosis and 258 (75.6%) grade 3 steatosis. In Group B (155 patients), 64 patients (41.2%) showed grade 2 steatosis, 89 (57.4%) grade 3 of steatosis, and 2 (1.3%) patients grade 4 of steatosis. In Group C (151 patients), 74 patients (49%) showed grade 2 steatosis and 77 patients (50.9%) grade 3 steatosis. The two patients with grade 4 of steatosis have been further studied and were defined as non-alcoholic steatohepatitis (NASH); they represent 0.3% of the NAFLD patients.

Nobody in the control group showed steatosis (Table 1).

AUDIT (WHO) measures indicated an average score of 6.4 (SD=2.1) in 568 NAFLD patients and 7.8 (SD=1.3) in 79 NAFLD patients. Group D AUDIT score was of 6.6 (SD=2.5) in 579 patients and 7.2 (SD=3.1) in 74 patients.

The demographic values, i.e., age, gender, and educational levels were not significantly associated with NAFLD. One-way analysis of variance (ANOVA) method was applied to explore the statistically significant difference among mean value in three groups of NAFLD and control (Table 2). The neurological pathologies did not differ in the groups (Table 3). Group A, with chronic headaches; Group B, with sleep disorders and Group C with a precedent transient ischemic attack (TIA) have been studied and compared for neuropsychological results. All the three groups of NAFLD showed

Table 1

Steatosis as defined by Third National Health and Nutrition Exa. Survey, 2010 (number of patients and %).

Steatosis	Group A (341 pts)	Group B (155 pts)	Group C (151 pts)	Group D (653 pts)
Grade 1 = none	0	0	0	653 (100%)
Grade 2 = mild	83 (24.3%)	64 (41.2%)	74 (49%)	0
Grade 3 = moderate	258 (75.6%)	89 (57.4%)	77 (50.9%)	0
Grade 4 = severe	0	2 (1.3%)	0	0

Table 2

Comparison of mean values of various biochemical parameters in the three groups and controls (Means and SD).

Variable (normal values)	Group A (341)	Group B (155)	Group C (151)	Controls (653)	F chi2 value	DF	p-Value
Age (years)	54.1 (2.1)	57.3 (1.4)	56.7(1.2)	59.1(1.4)	2.66	2.24	0.63
Educational level (yrs)	7.7 (1.3)	7.9 (1.1)	8.1 (1.7)	8.2 (0.9)	0.67	3.11	0.45
Gender M/F	187/166	91/70	82/69	352/301	0.79	2.31	079
Hb1Ac (%)	6.2 (0.3)	6.3 (0.1)	6.7 (0.2)	5.3 (0.7)	0.67	3.11	0.05
Cholesterol (mg/dl)	207.4 (24.1)	215.5 (21.3)	213 (20.7)	167.7 (10.3)	0.71	3.21	0.05
Triglycerides (mg/dl)	139.4 (17.6)	144.6 (21.5)	147.7 (20.1)	110.1 (10.7)	0.75	3.13	0.01
HDL (mg/dl)	31.7 (10.2)	29.7 (5.7)	28.7 (12.3)	33.2 (5.7)	0.67	2.45	0.63
LDL (mg/dl)	147.8 (10.1)	156.8 (15.3)	154.7 (13.6)	114.18 (7.1)	0.69	2.7	0.01
vitamin DOH25 (20–100 mg/dl)	12.7 (1.5)	11.7 (2.9)	13.4 (1.2)	22.9 (3.7)	2.66	2.5	0.01
Folate (3.8–26 ng/ml)	2.4 (1.1)	1.8 (1.1)	2.1 (1.1)	5.1 (1.1)	0.71	2.15	0.01
Vitamin B12 (201–870 pg/ml)	129.2 (11.7)	111.7 (21.3)	112.4 (12.3)	237.2 (12.5)	0.91	2.32	0.01
Homocysteine (3–15 mcml/l)	19.3 (2.1)	17.3 (2.5)	19.7 (3.9)	19.7 (3.4)	5.77	2.41	0.01
ALT (U/l)	54.1 (7.1)	57.7 (8.1)	52.3 (3.1)	21.3 (1.1)	3.41	2.31	0.01
AST (u/L)	38.7 (6.2)	35.7 (3.2)	37.9 (3.1)	18.1 (1.3)	2.75	2.41	0.01
BMI (num. and %)							
<18.5	17 (4.9%)	15 (9.6%)	8 (5.2%)	57 (8.7%)	0.79	3.21	0.43
18.5–24.9	32 (9.3%)	17 (10.9%)	14 (9.2%)	152 (23.4%)	0.87	2.48	0.05
25–29.9	105 (30.7%)	56 (36.1%)	49 (32%)	284 (43.3%)	0.81	3.41	0.05
30–34.9	137 (40.1%)	60 (38.7%)	67 (44.3%)	155 (23.7%)	0.82	3.46	0.01
>35	50 (14.7%)	7 (4.6%)	13 (8.6%)	5 (0.7%)	0.87	3.23	0.01

Table 3

Neurological conditions in the two groups considered.

Neurological condition	NAFLD			Not-NAFLD	Control group
	Group A	Group B	Group C		
Cervicogenic headaches	359	0	0	384	
Migraine	0	161	0	146	
Transient ischemic attacks	0	0	151	157	

a significant increase of glycosylated hemoglobin ($p < 0.05$), of total cholesterol ($p < 0.05$), triglycerides ($p < 0.01$), and of LDL ($p < 0.01$) than controls. They showed a decreased level of vitamin D-OH25 ($p < 0.01$), folate ($p < 0.01$), vitamin B12 ($p < 0.01$), elevated levels of homocysteine ($p < 0.01$), and higher levels of AST and ALT ($p < 0.01$), than controls.

As expected, there is a higher percentage of increased BMI (30–35 or more) in NAFLD ($p < 0.01$) than controls. Moreover, there is a higher percentage of not-hemodynamic stenosis (50–75%) in NAFLD (Table 4).

Patients of the three groups did worse in the FAB test than controls ($p < 0.05$) showing more severe executive alterations. They showed higher levels of depressive mood (according to Beck's test) ($p < 0.01$) than controls. At the same time, they showed greater anxiety, according to HAM-A ($p < 0.01$) when compared to controls and higher levels of apathy (AES-C) ($p < 0.01$) (Table 5). Moreover, they made higher quantities of interference mistakes in STROOP test than controls ($p < 0.01$).

We have considered four biochemical variables (low folate, vitamin B12, low vitamin D-OH25, and high homocysteine) and found them significantly different in the three Groups (Table 6). In NAFLD groups, the mean level of vitamin D-OH was lower than controls ($p < 0.01$) (Table 6), and as seen in Table 3, Group A population was entirely in an insufficiency condition, whereas Group B in a deficiency status (NOS Criteria [20]).

In NAFLD populations, mean Hcy levels were higher than in controls ($p < 0.01$) (Table 6), as well as folate and vitamin B12 levels, were significantly lower than controls ($p < 0.01$) (Table 6). The Multiple-comparison Tukey Test confirmed these results (Table 7).

As demonstrated by the Univariate Regression Analysis, as shown in Table 8, crude odds ratios are significant for the association between NAFLD and vitamin insufficiency and deficiency, folate and vitamin B12 deficiency and high level of homocysteine. At the same time, there is a positive association between NAFLD and low performances in FAB and Interference Part of Stroop test, higher levels of Beck Hamilton and AES-C test.

The presence of a relationship between them was checked based on the statistical significance of the final model chi-square, and the existence of a relationship was established. All the independent variables, excepted age, sex, and educational level, had significant contributions toward NAFLD groups (Table 9).

The regression coefficient (B) for the vitamin D-OH25 was -0.46 for NAFLD; it indicates that the increase of vitamin D-OH25 decreased the likelihood of NAFLD, with an exponential B value 0.82 , which implies that for an increase of vitamin D levels, the odds of having NAFLD decreased by 18%. The regression coefficient (B) for the folate was -0.98 for NAFLD; it indicates that the increase of vitamin D-OH25 decreased the likelihood of NAFLD, with an exponential B value 0.82 , which implies that for an increase of folate levels, the odds of having NAFLD decreased by 9%. The regression coefficient (B) for the vitamin B12 was -0.87 for NAFLD; it indicates

Table 4
Doppler results.

Doppler	Group A (341)	Group B (155)	Group C (151)	Controls (653)	F chi2 value	DF	p-Value
Intimal medial thickening	293 (85.9%)	97(62.5%)	20 (13.5%)	453 (69.3%)	0.27	2.17	0.63
Stenosis < 50%	24 (7.1%)	40 (25.8%)	97 (64.2%)	116 (17.8%)	0.37	2.21	0.01
Stenosis 50–75%	23(6.9%)	17 (0.9%)	31 (20.5%)	84 (12.6%)	1.17	2.19	0.01
Stenosis > 75%	1(0.3%)	1 (0.6%)	3 (1.9%)	0 (0%)	4.31	2.41	0.54
Occlusion	0	0	0	0	0	0	0

Table 5
Comparison of mean values of neuropsychological tests in the three groups and controls (Means and SD).

Characteristics	Group A (341)	Group B (155)	Group C (151)	Controls (653)	F chi2 value	DF	p-Value
<i>FAB test</i>	11.3 (2.5)	11.6 (1.7)	10.9 (2.1)	115.6 (1.2)	0.87	2.43	0.01
<i>Beck's test</i>	27.1(1.3)	28.3 (2.7)	29.1 (2.3)	12.7 (1.3)	0.74	2.9	0.01
<i>HAM-A test</i>	36.4 (2.7)	31.3 (1.3)	27.1(3.1)	16 (2.1)	0.08	2.02	0.01
<i>AES-C</i>	24.3 (1.7)	26.7 (2.1)	27.1 (2.7)	11(2.1)	0.37	2.42	0.01
<i>Stroop test</i>							
Reading (correct)	84.5(2.7)	86.7 (2.1)	83.1 (1.7)	91.1 (1.7)	0.75	2.41	0.36
Color naming (correct)	61.7(3.1)	63.1(2.7)	64.1 (1.9)	67.1 (1.3)	0.77	2.34	0.54
Interference mistakes (correct)	31.9(2.1)	32.7 (3.1)	31.1 (1.7)	17.3 (1.7)	0.89	2.48	0.01

Table 6
Comparison of mean values of specific biochemical (divided by different levels) and neuropsychological parameters in the three groups and controls (Means and SD).

Variable (normal values)	Group A (341)	Group B (155)	Group C (151)	Controls (653)	F chi2 value	DF	p-Value
vit D-OH25 <12 ng/ml	0	11.7 (2.9)	0	0	0.67	2.25	0.01
vit D-OH25 12–20 ng/ml	12.7 (1.5)	0	13.4 (1.2)	0	0.87	2.13	0.01
vit D-OH25 >25 ng/ml	0	0	0	22.9 (3.7)	0.71	2.6	0.01
Hcy (3–14 mcml/l)	0	0	0	11.1 (3.4)	0.34	2.11	0.01
Hcy (15–30 mcml/l)	19.3 (2.1)	17.8 (2.5)	19.7 (3.9)	0	0.71	2.34	0.01
Folate (0.5–3.7 ng/ml)	2.4 (1.1)	1.8 (1.1)	2.1 (1.1)	0	0.47	2.17	0.01
Folate (3.8–26 ng/ml)	0	0	0	5.1 (1.1)	0.23	2.41	0.01
Vitamin B12 (90–204 pg/ml)	129.2 (11.7)	111.7 (21.3)	112.4 (12.3)	0	0.77	2.35	0.01
Vitamin B12 (205–870 pg/ml)	0	0	0	237.2 (12.5)	0.87	2.6	0.01

that the increase of vitamin D-OH25 decreased the likelihood of NAFLD, with an exponential B value 0.85, which implies that for an increase of vitamin B12 levels, the odds of having NAFLD decreased by 7%. The regression coefficient (B) for the homocysteine was +0.57 for NAFLD; it indicates that the decrease of homocysteine decreased the likelihood of NAFLD, with an exponential B value 0.98, which implies that for a decrease of homocysteine levels, the odds of having NAFLD decreased by 15%.

In order to evaluate the relationship between NAFLD and cognitive and behavioral impairment, we performed a multivariate linear regression analysis: in model 1, we adjusted for sex, age, educational level and in model 2 we further adjusted for vitamin D-OH25, folate, vitamin B12, and homocysteine (Table 10).

FAB, Beck, HAM-A, AES-C and Interference Mistakes number failed to have a lower score concerning age, sex, and educational levels (see all the model 1 regression in Table 9). On the other hand, compared to controls, NAFLD patients had lower performances on FAB, higher scores in Beck, HAM-A, and AES-C and higher Interference Number of mistakes in Stroop test after controlling for vitamin D-OH25, folate, vitamin B12 and homocysteine (respectively: FAB: $B=0.72$, 95% CI: 0.105–1.347, $p<0.01$; Beck: $B=0.88$, 95% CI: 0.97–10.65, $p<0.01$; HAM-A: $B=0.74$, 95% CI: 0.32–2.31, $p<0.01$; AES-C: $B=0.65$, 95% CI: 0.4–2.6, $p<0.01$; Interference Mistakes Stroop Test: $B=0.87$, 95% CI: 0.3–2.3, $p<0.05$).

The classification accuracy rate of the logistic model was 56.7%, which was higher than the proportional by chance accuracy; the criteria for the classification accuracy were satisfied.

Finally, we did not find a correlation between higher levels of Beck Scores and lower FAB scores, or higher Interference mistakes test. We did not find any relation between higher levels of HAM-A and lower FAB scores or higher Interference mistakes test. We did find a not-significant, but effective relation between higher levels

of AES-C and lower FAB scores ($r=-0.67$, $p=0.064$, Spearman's correlation coefficient), but not with higher Interference mistakes test. As expected, we did find a positive correlation between Beck's score and HAM-A ($r=0.89$, $p<0.01$) (Spearman's correlation coefficient), but any with AES-C.

4. Discussion

This work is a cross-sectional study, covering 647 NAFLD-neurological outpatients, and 653 control-outpatients.

We testified that NAFLD, following data previously published, related to common vascular risk factors, such as lipid assessment and lower HDL levels, Hb1ac, AST and [9,11,32,33] and obesity [34,35].

NAFLD has been only recently related to lower levels of vitamin B complex [36], it has been shyly related to higher level of homocysteine [37], and finally, it has been tightened to lower levels of vitamin D (independent to body mass and obesity status) [38,39].

To our knowledge, this is the first work which reported a positive correlation with NAFLD and low levels of vitamin B12, folate, and vitamin D and with higher levels of homocysteine. Moreover, we documented that for an increase of vitamin D levels, the odds of having NAFLD decreased by 18%; for an increase of folate levels, the odds of having NAFLD decreased by 9%; for an increase of vitamin B12 levels, the odds of having NAFLD decreased by 7%, and for a decrease of homocysteine levels, the odds of having NAFLD decreased by 15%.

We demonstrated a higher percentage of not-hemodynamic carotid stenosis (50–75%) in NAFLD than in the control group, in line with other works [40].

Our work has also demonstrated a significant association between NAFLD and low scores of FAB and with a higher number

Table 7
Multiple comparison analysis (Tukey test) of various biochemical and neuropsychological parameters in the four groups.

Variables	Mean Differences	SE of mean differences	p-Value
<i>Vitamin D-OH25</i>			
A vs D	-10.2	-2.1	0.05
B vs D	-11.2	-1.96	0.01
C vs D	-9.5	-1.7	0.01
<i>Folate</i>			
A vs D	-2.7	-0.1	0.01
B vs D	-3.3	-0.3	0.01
C vs D	-3.0	-0.7	0.01
<i>Homocysteine</i>			
A vs D	+8.1	0.6	0.01
B vs D	+6.2	0.7	0.01
C vs D	+8.6	1.1	0.01
<i>Vitamin B12</i>			
A vs D	-101.7	-10.1	0.01
B vs D	-119.7	-12.3	0.01
C vs D	-118.6	-11.7	0.01
<i>FAB</i>			
A vs D	-4.3	-1.1	0.01
B vs D	-4.6	-0.7	0.01
C vs D	-4.1	-1.2	0.01
<i>HAM-A</i>			
A vs D	+20.4	+3.4	0.01
B vs D	+15.7	+3.7	0.01
C vs D	+21.1	+2.7	0.01
<i>Beck</i>			
A vs D	+14.4	+2.3	0.01
B vs D	+15.6	+3.1	0.01
C vs D	+16.4	+2.7	0.01
<i>AES-C</i>			
A vs D	+13.3	+2.1	0.01
B vs D	+15.7	+1.9	0.01
C vs D	+16.1	+1.6	0.01
<i>Interference mistakes Stroop</i>			
A vs D	+14.6	+2.5	0.01
B vs D	+15.4	+2.9	0.01
C vs D	+13.8	+2.1	0.01

Table 8
Univariate regression analysis.

Dependent variable	Independent variable	Odds ratio	95%CI	p
NAFLD	vit D-OH25 insufficiency	5.4	10.93–13.56	0.023
	vit D-OH deficiency	4.3	8.93–11.56	0.01
	Folate	3.9	2.1–4.2	0.037
	vit. B12	2.7	29.3–36.7	0.034
	Hcy	4.5	17.3–19.7	0.036
	FAB	2.7	10.9–11.8	0.045
	BECK	2.3	12.7–29.1	0.047
	HAmilton Anxiety	5.73	11.2–31.1	0.011
	Interference Mistakes	5.4	12.3–35.7	0.019

Table 9
Summary of multinomial logistic regression analysis.

Variables		Univariate assoc.			Regression coefficient (B)	SE	p-Value	EXP (B)	95% CI for exp. (B)
Dependent	Independent	OR	95% CI	p-Value					
NAFLD	Age	1.1	1.1–2.3	0.76	0.023	0.015	0.6	1.01	0.9–1.03
	Sex	1.3	1–2.1	0.85	0.066	0.28	0.5	1.1	0.5–0.97
	Educ. levels	1.1	0.9–1.7	0.67	0.079	0.23	0.7	1.1	0.4–0.98
	Vit.DOH-25	4.5	4.3–7.1	0.023	-0.46	0.12	0.01	0.82	2.5–10.11
	Folate	4.2	2.1–5.7	0.041	-0.98	0.17	0.01	0.91	2.1–9.1
	Vitamin B12	4.1	1.2–9.1	0.05	-0.97	0.01	0.04	0.87	2.2–4.7
	Homocysteine	5.6	1.9–8.4	0.01	+0.57	0.65	0.01	0.98	1.3–4.7

Table 10
Association between NAFLD and neuropsychological variables with a multivariate linear regression analysis.

	B	p-Value	SE	95%CI
<i>FAB</i>				
Model 1	0.54	0.6	3.56	0.48–1.1
Model 2	0.72	0.01	3.76	0.105–1.347
<i>Beck</i>				
Model 1	0.12	0.7	3.1	0.002–0.21
Model 2	0.88	0.01	3.44	0.97–10.65
<i>HAM-A</i>				
Model 1	0.32	0.5	3.23	0.012–0.023
Model 2	0.74	0.01	3.56	0.32–2.31
<i>AES-C</i>				
Model 1	0.34	0.56	3.4	0.092–0.2
Model 2	0.65	0.01	4.2	0.4–2.6
<i>Interference Mistakes Stroop Test</i>				
Model 1	6.67	0.67	3.65	0.5–13.1
Model 2	0.87	0.05	3.4	0.3–2.3

Model 1 adjusted for age (continuous), sex (m/f), educational levels (years school). Model 2 adjusted for vitamin D-OH25, folate, vitamin B12 and homocysteine.

of interference mistakes [30], higher scores of Beck and Hamilton Anxiety Test. Finally, a multivariate linear regression analysis, as shown in our model 2, NAFLD patients had lower performances on FAB, higher scores in Beck, HAM-A, and AES-C and higher Interference Number of mistakes in Stroop test after controlling for vitamin D-OH25, folate, vitamin B12, and homocysteine.

Various studies have demonstrated that obese subjects have lower folate serum levels in comparison with normal-range BMI subjects [41,42]. Furthermore, obesity is a well-known risk factor for NAFLD, as shown in our study too [43]. Therefore, it has been suggested that folate deficiency may have a pathogenic role in NAFLD [36], and it leads to a more severe form of the disease, mainly in metabolic syndrome and diabetes mellitus type 2 patients [43]. Moreover, Sid et al. [43] stressed the importance of folate in the progression of NAFLD, thus raising the possibility that supplemental folate may be a treatment option (confirmed by Xia et al. [44]).

Another important finding of this study was the role of low vitamin B12 levels as an independent predictor of NAFLD: it has been hypothesized a relationship between vitamin B12 low scores and NASH histological severity, and fibrosis grade [36]. These results corroborated previous studies, which demonstrated that NAFLD patients have lower serum levels of vitamin B12 in comparison to controls [45–47] and are in contrast with some others [48,49]. In another study [50,51], higher levels of homocysteine were observed in 71 NAFLD patients, which correlated negatively with folate and B12 concentrations. Therefore, Mahamid et al. [36] speculated that low levels of vitamin B12 might predict the development of a severe form of NASH; high levels may indicate the commencement of end-stage liver disease.

Even more difficult is to explain the dysexecutive and attention disorders showed in our NAFLD patients, associated with a somewhat increased level of depression and anxiety. The cognitive alterations observed in our study were in line, with that described by Won Seo et al. [3]: the magnitude of the association with NAFLD was robust and persisted when other vascular factors have been included in models. As suggested by Won Seo et al. [3] it remains possible that the association between NAFLD and cognitive impairment could be an epiphenomenon, mainly due to the superimposing cardiovascular risk factors, characteristic of the two conditions (NAFLD and cognitive impairment) or due to an inflammatory condition (common to NAFLD and cognitive impairment [35,52–55]). Our patients, though, underwent to neuroimaging, and we did not find any significant vascular alteration. The behavioral disturbances studied in our work reflected

that NAFLD was more depressed and more anxious (in accordance to previous studies, i.e. [56–59]), and as imagined, there is a positive correlation between depression and anxiety scores. Curiously, none of the patients recruited in the study auto-defined themselves as depressed or anxious. To our best knowledge, this is the first study which analyzes apathy score and found out that NAFLD related with a higher score of apathy, which did not relate to depression or anxiety [60]. There is a single work [61] that, employing near-infrared spectroscopy (NIRS), found out that Japanese women, with NAFLD, were more depressed, with less concentration and showed a minor value of oxy-Hb concentration in the frontal lobe.

NIRS technique is not entirely and universally accepted [61,62], but it is suggestive of supporting our findings, which are strongly related to frontal-subcortical suffering.

One of the open questions could be if the observed spectrum could be a primary effect, concerned somehow to NAFLD or secondary to all the vascular factors, which are super-imposed to NAFLD? In accordance to the Literature, NAFLD comprises metabolic risk factors, such as hypertension, higher triglycerides level, higher LDL and lower HDL, diabetes, and obesity, and even the combination of all the risk factors [63–65]. Since we have considered two neurological populations, indeed, one with NAFLD and the other without it, the metabolic syndrome, which characterized NAFLD, did not influence neurological pathologies, per se. The two groups are matched for neurological comorbidities, which did not seem to be related to the metabolic factors we found in the NAFLD group. On the other hand, the other neuropsychological spectrum of symptoms, i.e., apathy, depression, dysexecutive functions, has been observed in NAFLD group. The question remains unsolved: are they related to NAFLD or the metabolic symptoms bound to NAFLD? If so, behavior and vascular risks could even be more pronounced in patients with NASH: a further possibility for future studies could be the comparison of NAFLD and NASH population; this will hopefully give more data, with a healthy group to better understand the real role of liver alteration in the neuropsychological profile.

Our study has several limitations, being a single-center study with a small number of recruited patients and therefore with clear limits to interfere; the study has a cross-sectional design, and it does not have any pathological confirm. On the other hand, all our patients can be thoroughly studied in a standardized way, which means careful neuroimaging, LABS, Ultrasonography, and neuropsychological examinations. This way, we applied homogenous and well-accepted criteria to study our groups, NAFLD and healthy controls. The control group, matched for age, educational level and sex

differences have the same neurological conditions than the other group and can be thoroughly studied.

Our data were the first to relate vitamin B12 and D, folate, and homocysteine and different neuropsychological variables to NAFLD, having excluded alcohol consumption.

More studies will be needed to implement further knowledge.

Conflict of interest

The authors have no conflicts of interest to declare.

References

- [1] Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KW, Chalasani N, Lavine JE, et al. End-points and clinical trial design for nonalcoholic steatohepatitis. *Hepatology* 2011;54:344–53.
- [2] Sattar N, Forrest E, Preiss D. Non alcoholic fatty liver disease. *BMJ* 2014;349:g4596, <http://dx.doi.org/10.1136/bmj.g4596>.
- [3] Won Seo S, Gottesamn RF, Clark JM, Hernaez R, Chang Y, Kim C, et al. non alcoholic fatty liver disease is associated with cognitive function in adults. *Neurology* 2016;22(86):1136–42.
- [4] Fargion S, Porzio M, Fracanzani AL. Nonalcoholic fatty liver disease and vascular disease: state of the art. *World J Gastroenterol* 2014;20(37):13306–24.
- [5] Lazo M, Clark JM. The epidemiology of non alcoholic fatty liver disease: a global perspective. *Semin Liver Dis* 2008;339–50.
- [6] Ratziu V, Bellentani S, Cortez-Pinto H, Day C, MArchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. *J Hepatol* 2010;53:372–84.
- [7] Kneeman JM, Misdraggi J, Corey KE. Secondary causes of nonalcoholic fatty liver disease. *Therap Adv Gastroent* 2012;5(3):199–207.
- [8] Khoonsari M, Azar MMH, Ghavam R, Hatami K, Asobar M, Gholami A, et al. Clinical manifestations and diagnosis of nonalcoholic fatty liver disease. *Ir J Pathol* 2017;82(12):99–105.
- [9] Stepanova M, Younoussi ZM. Independent association between non alcoholic fatty liver disease and cardiovascular disease in the US population. *Clin Gastroenterol Hepatol* 2012;10:646–50.
- [10] Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. *Hypokrata* 2009;13(1):9–19.
- [11] Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with non alcoholic fatty liver disease. *N Engl J Med* 2010;363:1341–50.
- [12] De Caterina R, Zampolli A, Madonna R, Fioretti P, Vagnuzzo D. New cardiovascular risk factors: homocysteine and vitamins involved in homocysteine metabolism. *Ital Heart J* 2004;5(Suppl. 6):19S–24S.
- [13] Sadeghian S, Fallahi F, Salarifar M, Davoodi G, Mahmoodian M, Fallah N, et al. Homocysteine, vitamin B12 and folate levels in premature coronary artery disease. *BMCCardiovasc Disord* 2006;6:38, <http://dx.doi.org/10.1186/1471-2261-6-38>. Published 2006 Sep 26.
- [14] Mohan M, Kulkarni MV, Garg MK, Naik SS. Vitamin B12 deficiency and hyperhomocysteinemia as correlates of cardiovascular risk factors in Indian subjects with coronary artery disease. *J Cardiol* 2013;61(4):289–94.
- [15] Mandarin NR, Júnior FD, Salgado JV, Lages JS, Filho NS. Is vitamin d deficiency a new risk factor for cardiovascular disease? *Open Cardiovasc Med J* 2015;9:40–9, <http://dx.doi.org/10.2174/1874192401509010040>.
- [16] Moretti R, Caruso P, Dal Ben M, Conti C, Gazzin S, Tiribelli C. Vitamin D, homocysteine, and folate in subcortical vascular dementia and Alzheimer dementia. *Front Aging Neurosci* 2017, May, <http://dx.doi.org/10.3389/fnagi.2017.00169>.
- [17] WHO, IDF. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. 2006. Geneva.
- [18] Weykamp C. HbA1C: a review of analytical and clinical aspects. *Ann Lab Med* 2013;33:393–400, <http://dx.doi.org/10.3343/alm.2013.33.6.393>.
- [19] Friedwald WT, Lewy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 1972;18:499–502.
- [20] Aspray TJ, Bowring C, Fraser W, Gittoes N, Javaid MK, Mac Donald H, et al. National osteoporosis society vitamin D guideline summary. *Age Ageing* 2014;43:592–5, <http://dx.doi.org/10.1093/ageing/afu093>.
- [21] Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. *Am J Gastroenterol* 2003;98:960–967.
- [22] Becker U, Deis A, Sorensen TL, Gronbaek M, Borch-Johnsen K, Muller CF, Schnohr P, Jensen G. Prediction of risk of liver disease by alcohol intake, sex and age: a prospective population study. *Hepatology* 1996;23:1025–9.
- [23] Sattar N, Forrest E, Preiss D. Non alcoholic fatty liver disease. *BMJ* 2014;349:g4596.
- [24] Dubois B, Pillon B, Slachevsky A, Litvan I. Frontal Assessment Battery at bedside. *Neurology* 2000;55:1621–6.
- [25] Apollonio I, Leone M, Isella V, Piamarta F, Consoli T, Villa ML, et al. The Frontal Assessment Battery: normative values in an Italian population sample. *Neurol Sci* 2005;26:108–16, <http://dx.doi.org/10.1007/s10072-005-0443-4>.
- [26] Beck AT, Steer RA, Brown GK. Beck Depression Inventory–Second Edition. Manual. San Antonio, TX: The Psychological Corporation; 1996.
- [27] Ghisi M, Flebus GB, Montanaro A, Sanavio E, Sica C. Beck Depression Inventory II: Manuale Italiano. Firenze: Organizzazioni Speciali; 2006.
- [28] Hamilton M. The assessment of anxiety states by rating. *Br J Med Psychol* 1959;32:50–5. Italian Validation; Technology Systems Healthcare.
- [29] Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the apathy evaluation scale. *Psych Res* 1991;38(2):143–62.
- [30] Stroop JR. Studies of interference in spatial and verbal reactions. *J Exp Psychol* 1935;18:643–62.
- [31] Valgimigli S, PAdovani R, Budriessi C, Leone ME, Lugli D, Nichelli PF. Test di Stroop: dati normative Italiani di una versione cartacea per l'uso clinic. *Giornale It Psicol* 2010;37:945–53.
- [32] Targher G, Bertolini L, Poli F, et al. Non alcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. *Diabetes* 2005;54:3541–6.
- [33] Lazo M, Hernaez R, Bonekamp S, et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. *BMJ* 2011;343:d6891.
- [34] de Piano A, Estadella D, Oyama LM, Ribeiro EB, Damoso A, da Penha Olier de Nascimento C. Nonalcoholic fatty liver disease (NAFLD), a manifestation of the metabolic syndrome: new perspectives on the nutritional therapy. *Endocrinol Metab Syndr* 2014;3:3, <http://dx.doi.org/10.4172/2161-1017.1000135>.
- [35] Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. *Nature* 2006;444:875–80.
- [36] Mahamid M, Mahroum N, Bragazzi NL, Shalata K, Yane Y, Adawi M, Amital H, Watad A. Folate and B12 levels correlate with histological severity in NASH patients. *Nutrients* 2018;10(4):440, <http://dx.doi.org/10.3390/nu10040440>. Published 2018 Apr 2.
- [37] Barchetta I, Angelico F, Del Ben M, BAroni MG, Pozzilli P, et al. Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. *BMC Med* 2011;9:85.
- [38] Barchetta I, Carotti S, Labbadia G, Gentilucci UV, Muda AO, et al. Liver vitamin D receptor, CYP2R1 and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with non alcoholic steatohepatitis or hepatitis C virus. *Hepatology* 2012;56:2180–7.
- [39] Wendell CR, Zonderman AB, Metter EJ, Najjar SS, Waldstein SR. Carotid intimal medial thickness predicts cognitive decline among adults without clinical vascular disease. *Stroke* 2009;40:3180–5.
- [40] Casanueva E, Drijanski A, Fernández-Gaxiola AC, Meza C, Pfeffer F. Folate deficiency is associated with obesity and anemia in Mexican urban women. *Nutr Res* 2000;20:1389–94, [http://dx.doi.org/10.1016/S0271-5317\(00\)80020-2](http://dx.doi.org/10.1016/S0271-5317(00)80020-2).
- [41] Hirsch S, Poniachick J, Avendano M, Csendes A, Burdiles P, Smok G, Diaz JC, de la Maza MP. Serum folate and homocysteine levels in obese females with non-alcoholic fatty liver. *Nutrition* 2005;21:137–41, <http://dx.doi.org/10.1016/j.nut.2004.03.022>.
- [42] Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic and clinical implications. *Hepatology* 2010;51:679–89, <http://dx.doi.org/10.1002/hep.23280>.
- [43] Sid V, Siow YLOK. Role of folate in nonalcoholic fatty liver disease. *Can J Physiol Pharmacol* 2017;95:1141–8, <http://dx.doi.org/10.1139/cjpp-2016-0681>.
- [44] Xia MF, Bian H, Zhu XP, Yan HM, Chang XX, Zhang LS, et al. Serum folic acid levels are associated with the presence and severity of liver steatosis in Chinese adults. *Clin Nutr* 2017, <http://dx.doi.org/10.1016/j.clnu.2017.06.021>.
- [45] Koplay M, Gulcan E, Ozkan F. Association between serum Vitamin B12 levels and the degree of steatosis in patients with nonalcoholic fatty liver disease. *J Investig Med* 2011;59:1137–40, <http://dx.doi.org/10.2310/JIM.0b013e31822a29f5>.
- [46] Mechie NC, Goralczyk AD, Reinhardt L, Mihm S, Amanzada A. Association of serum Vitamin B12 levels with stage of liver fibrosis and treatment outcome in patients with chronic hepatitis C virus genotype 1 infection: a retrospective study. *BMC Res Notes* 2015;8(260), <http://dx.doi.org/10.1186/s13104-015-1248-z>.
- [47] Goel A, Ramakrishna B, Muliyl J, Madhu K, Sajith KG, Zachariah U, et al. Use of serum Vitamin B12 level as a marker to differentiate idiopathic noncirrhotic intrahepatic portal hypertension from cryptogenic cirrhosis. *Dis Dig Sci* 2013;58:179–87, <http://dx.doi.org/10.1007/s10620-012-2361-7>.
- [48] Polyzos SA, Kountouras J, Patsiaoura K, Katsiki E, Zafeiriadou E, Zavos C, et al. Serum Vitamin B12 and folate levels in patients with non-alcoholic fatty liver disease. *Int J Food Sci Nutr* 2012;63:659–66, <http://dx.doi.org/10.3109/09637486.2011.649249>.
- [49] Baltaci D, Kutlucan A, Turker Y, Yilmaz A, Karacam S, Deler H, et al. Association of Vitamin B12 with obesity, overweight, insulin resistance and metabolic syndrome, and body fat composition; primary care-based study. *Med Glas* 2013;10:203–10.
- [50] Gulsen M, Yesilova Z, Bagci S, Uygun A, Ozcan A, Arcin CN, et al. Elevated plasma homocysteine concentrations as a predictor of steatohepatitis in patients with non-alcoholic fatty liver disease. *J Gastroenterol Hepatol* 2005;20:1448–55, <http://dx.doi.org/10.1111/j.1440-1746.2005.03891.x>.
- [51] Polyzos SA, Kountouras J, Patsiaoura K, Katsiki E, Zafeiriadou E, Deretzi G, et al. Serum homocysteine levels in patients with nonalcoholic fatty liver disease. *Ann Hepatol* 2012;11(1):68–76.
- [52] Kim DG, Krenz A, Toussaint LE, Maurer KJ, Robinson SA, Yan A, et al. Non-Alcoholic fatty liver disease induces signs of Alzheimer's disease (AD) in wild-type mice and accelerates pathological signs of AD in an AD model. *J Neuroinflamm* 2016;13:1, <http://dx.doi.org/10.1186/S12974-15-0467-S>.
- [53] Villanova N, Moscattello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, Zoli M, Marchesini G. Endothelial dysfunction and cardiovascular risk profile in non alcoholic fatty liver disease. *Hepatology* 2005;42:473–80.

- [54] Rosenberg GA, Bjerke M, Wallin A. Multimodal markers of inflammation in the subcortical ischemic vascular disease type of vascular cognitive impairment. *Stroke* 2014;45:1531–8.
- [55] Takeda S, Sato N, Morishita R. Systemic inflammation, blood brain barrier vulnerability and cognitive/non cognitive symptoms in Alzheimer disease: relevance to pathogenesis and therapy. *Front Aging Neurosci* 2014;6:171–9.
- [56] Elwing JE, Lustman PJ, Wang HL, Clouse RE. Depression, anxiety, and non alcoholic steatohepatitis. *PSychosom Med* 2006;68:563–9.
- [57] Weinstein AA, Kallman Price J, Stepanova M, Poms LW, Fang Y, Moon J, et al. Depression in patients with nonalcoholic fatty liver disease and chronic viral hepatitis B and C. *Psychosomatics* 2011;52:127–32.
- [58] Youssef NA, Abdelmalek MK, Binks M, Guy CD, Omenetti A, Smith AD, et al. Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease. *Liver Int* 2013;33:1062–70.
- [59] Tomeno W, Kawashima K, Yoneda M, Saito S, Ogawa Y, Honda Y, et al. Non alcoholic fatty liver disease comorbid with major depressive disorder. The pathological features and poor therapeutic efficacy. *J Gastroenterol Hepatol* 2015;30:1009–14.
- [60] Moretti R, Signori R. Neural correlates for apathy: frontal–prefrontal and parietal cortical–subcortical circuits. *Front Aging Neurosci* 2016;8:289, <http://dx.doi.org/10.3389/fnagi.2016.00289>.
- [61] Takahashi T, Takikawa Y, Kawagoe R, Shibuya S, Iwano T, Kitazawa S. Influence of skin blood flow on near-infrared spectroscopy signals measured on the forehead during a verbal fluency task. *Neuroimage* 2011;57:991–1002.
- [62] Kirilina E, Jelzow A, Heine A, Niessing M, Wabnitz H, Bruhl R, et al. The physiological origin of task-evoked systemic artifacts in functional near infrared spectroscopy. *Neuroimage* 2012;61:70–81.
- [63] National Guide Centre UK: Non Alcoholic fatty liver disease. Assessment and management. London National Institute for Health and Care Excellence (UK): 2016, July. Nice Guideline, no 49, 5, Risk factors for NAFLD.
- [64] Brunt EM, Wong WW, Nobili V, Day CP, Sookolan S, Maher JJ, Bugianesi E, Sirlin CB, Neuschweinder-Teri BA, Rinella ME. Non alcoholic fatty liver disease. *Nat Rev Disease Primers* 2015;1:15080.
- [65] Azzam H, Malnick S. Non Alcoholic fatty liver disease: the heart of the matter. *World J Hepatol* 2015;7(10):1369–76.